http://www.aph.gov.au/LIBRARY/Pubs/RN/2004-05/05rn03.htmAUSFTA introduces procedural changes to this system that give drug manufacturers more opportunities to press for their drugs to be listed on the PBS (see figure 1). The most controversial of these changes has been the review mechanism for decisions not to list a drug.(5)
Some fear the review process will reduce or remove Australia’s control over the PBS listing process by overturning decisions made by the Committee.(6)
http://www.hinduonnet.com/fline/fl2204/sto...25002609700.htmThe New York Times said in an editorial on January 18 that the ordinance was heavily influenced by multinational and Indian drug-makers eager to sell patented medicines to India's huge middle class. Describing the decree as "a double hit that will cut off the supply of affordable medicines and remove generic competition that drives down the cost of brand-name drugs", the newspaper said that the ordinance was so tilted towards the pharmaceutical industry that it did not even take advantage of the rights countries enjoyed under the WTO regime to protect public health.